PDF(Pubmed)
Abstract：
OBJECTIVE: Sacubitril/valsartan (SV), a novel pharmacological class of angiotensin receptor neprilysin inhibitors, is effective in treating heart failure (HF) by inhibiting the degradation of natriuretic peptides and the renin-angiotensin-aldosterone system. However, no studies have observed the long-term effects of SV on patients with HF and preserved left ventricular ejection fraction (LVEF) undergoing hemodialysis (HD) over a long period.
METHODS: This single-center retrospective study of 21 months duration involved consecutive patients with HF and preserved LVEF undergoing HD, who received 50-200 mg/day. All patients were followed up regularly, and clinical, biochemical, and echocardiographic parameters were recorded at baseline and during follow-up. The efficacy and safety of SV were also analyzed.
RESULTS: This longitudinal study included nine patients, with a median age of 76 years. The median HD duration was 7 years. At baseline, the mean brain natriuretic peptide (BNP) was 133±73.6 pg/ml and that of LVEF was 66%±9%. After SV therapy, the systolic blood pressure, diastolic blood pressure, and heart rate decreased, albeit without statistical significance. BNP levels, LVEF, left atrial anteroposterior dimension, and left ventricular mass index did not change, compared to baseline values. No adverse effects were observed in any of the patients.
CONCLUSIONS: SV tended to decrease blood pressure and heart rate in patients with HF and preserved LVEF undergoing HD but did not alter cardiac function assessments, such as BNP or echocardiography.
METHODS: This single-center retrospective study of 21 months duration involved consecutive patients with HF and preserved LVEF undergoing HD, who received 50-200 mg/day. All patients were followed up regularly, and clinical, biochemical, and echocardiographic parameters were recorded at baseline and during follow-up. The efficacy and safety of SV were also analyzed.
RESULTS: This longitudinal study included nine patients, with a median age of 76 years. The median HD duration was 7 years. At baseline, the mean brain natriuretic peptide (BNP) was 133±73.6 pg/ml and that of LVEF was 66%±9%. After SV therapy, the systolic blood pressure, diastolic blood pressure, and heart rate decreased, albeit without statistical significance. BNP levels, LVEF, left atrial anteroposterior dimension, and left ventricular mass index did not change, compared to baseline values. No adverse effects were observed in any of the patients.
CONCLUSIONS: SV tended to decrease blood pressure and heart rate in patients with HF and preserved LVEF undergoing HD but did not alter cardiac function assessments, such as BNP or echocardiography.
摘要：
目的：沙库必曲/缬沙坦（SV），一种新的药理学类型的血管紧张素受体脑啡肽抑制剂，通过抑制利钠肽和肾素-血管紧张素-醛固酮系统的降解有效治疗心力衰竭（HF）。然而,没有研究观察到SV对长期接受血液透析(HD)且左心室射血分数(LVEF)保留的HF患者的长期影响.
方法：这项为期21个月的单中心回顾性研究涉及连续的HF患者和接受HD的LVEF保留患者，谁收到50-200毫克/天。所有患者均定期随访,临床,生物化学，在基线和随访期间记录超声心动图参数.同时对SV的疗效和安全性进行了分析。
结果：这项纵向研究包括9名患者，平均年龄为76岁。中位HD持续时间为7年。在基线,平均脑钠肽(BNP)为133±73.6pg/ml,LVEF为66%±9%.SV治疗后，收缩压,舒张压,心率下降，虽然没有统计学意义。BNP水平，LVEF,左心房前后尺寸,左心室质量指数没有变化，与基线值进行比较。在任何患者中均未观察到不良反应。
结论：SV倾向于降低HF患者的血压和心率，维持接受HD的LVEF，但不改变心功能评估。如BNP或超声心动图。
方法：这项为期21个月的单中心回顾性研究涉及连续的HF患者和接受HD的LVEF保留患者，谁收到50-200毫克/天。所有患者均定期随访,临床,生物化学，在基线和随访期间记录超声心动图参数.同时对SV的疗效和安全性进行了分析。
结果：这项纵向研究包括9名患者，平均年龄为76岁。中位HD持续时间为7年。在基线,平均脑钠肽(BNP)为133±73.6pg/ml,LVEF为66%±9%.SV治疗后，收缩压,舒张压,心率下降，虽然没有统计学意义。BNP水平，LVEF,左心房前后尺寸,左心室质量指数没有变化，与基线值进行比较。在任何患者中均未观察到不良反应。
结论：SV倾向于降低HF患者的血压和心率，维持接受HD的LVEF，但不改变心功能评估。如BNP或超声心动图。
